Oisin and its spinout OncoSenX completed antiaging trials using synolytics to extend the life of old mice by 20%. They will have human clinical trials starting in early 2020. They will apply it to people with solid tumors.
They use a lipid nanoparticle to deliver a DNA plasmid into sensescent (aka zombie) cells. The old cells are triggered to die and this boosts health and longevity.
At Ending Age-Related Diseases, John Lewis of Oisin Biotechnologies discussed senolytics, which are drugs that kill senescent cells. He explained the differences between healthy and senescent cells along with the senescence-associated secretory phenotype (SASP) responsible for systemic inflammation. He went into detail about senolytics and what his company looks for when creating them, including details about suicide genes and biomarkers of senescence. He also discussed issues with bringing these drugs to humans and suggested oncology as a possible method for bringing them to the clinic.
Brian Wang is a Futurist Thought Leader and a popular Science blogger with 1 million readers per month. His blog Nextbigfuture.com is ranked #1 Science News Blog. It covers many disruptive technology and trends including Space, Robotics, Artificial Intelligence, Medicine, Anti-aging Biotechnology, and Nanotechnology.
Known for identifying cutting edge technologies, he is currently a Co-Founder of a startup and fundraiser for high potential early-stage companies. He is the Head of Research for Allocations for deep technology investments and an Angel Investor at Space Angels.
A frequent speaker at corporations, he has been a TEDx speaker, a Singularity University speaker and guest at numerous interviews for radio and podcasts. He is open to public speaking and advising engagements.